Product Name Catalog # Price (NP)**   Qty
Control (Empty Vector) Ba/F3 Stable Cell Line EL-001-NP $1,200
- +
  • ** Non Profit (NP) price is for academic, non profit organizations and institutes

Epidermal  growth  factor  receptor  (EGFR)  is  a  cell-surface  receptor  with  intrinsic  intracellular  protein-tyrosine  kinase  (TK)  activity.  Ligand binding induces EGFR dimerization and phosphorylation, leading to the activation of EGFR signaling pathway.  In several malignancies   such   as   non-small   cell   lung   cancer (NSCLC),   EGFR   signaling   is   deregulated   due   to mutations  in  EGFR,  which  results  in  uncontrolled proliferation  and  migration  of  tumor  cells. EGFR mutations can lead to “oncogene-addicted” cancers, where the tumor cells depend on the mutated EGFR for cell survival and malignant phenotype.  One of the most   common   EGFR   mutations   found in human patients is L858R substitution in exon 21, within the activation loop of EGFR.    Patients  with  this  mutation are sensitive to EGFR tyrosine kinase inhibitors (TKIs) such  as  gefitinib  or  erlotinib,  whereas  patients  with wild  type  EGFR  are  not  sensitive  to  TKI.    Another clinically  relevant  mutation  associated  with  acquired gefitinib  and  erlotinib  resistance  is  T790M,  found  in exon  20.    Cells  expressing  EGFR  with  both  L858R and   T790M   mutations   are   resistant   to   induced apoptosis  in  the  presence  of  gefitinib  or  erlotinib.   


EL-001 is stable cell line established with an empty vector as a control for three  stably  expressing  HA-tagged  EGFR  Ba/F3  cell lines; WT   EGFR,   L858R EGFR mutant, L858R/T790M EGFR double mutant.  These cell   lines   can   be   used   to   study   the   molecular mechanism underlying susceptibility of tumors to the drugs (i.e. gefitinib and erlotinib) as well as screening and validating new TKIs.   


Dose-dependent growth inhibition of BaF3 cells harboring EGFR exon 20 insertion D770-N771insSVD mutation (EL-008), control Ba/F3 cell line (EL-001) and EGFR exon 20, A767-dupASV mutation (EL-010). The cells were treated with the indicated dose of erlotinib for 72 hours and cell viability was measured using Signosis CVC reagent. 



View user manual